Incyte (INCY) Capital Expenditures (2010 - 2026)
Incyte's (INCY) quarterly Capital Expenditures came in at $12.4 million in Q2 2026, down 34.92% YoY from $19.1 million in Q2 2025, and up 21.7% on a QoQ basis from $10.2 million in Q1 2026.
Incyte (INCY) Capital Expenditures (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Capital Expenditures data on file, last reported at $12.4 million in Q2 2026.
- Quarterly Capital Expenditures fell 34.92% year-over-year to $12.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $59.2 million (up 32.18% YoY) and the FY2025 annual result came in at $58.9 million, down 31.76% from the prior year.
- Capital Expenditures improved to $12.4 million in Q2 2026, from $10.2 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $54.1 million in Q2 2024 to a low of $2.3 million in Q4 2023.
- A 5-year average of $15.4 million and a median of $12.2 million in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 89.34% — and 2024, when it surged 666.83%.
- Tracing INCY's Capital Expenditures over 5 years: stood at $21.3 million in 2022, then plunged by 89.34% to $2.3 million in 2023, then surged by 666.83% to $17.4 million in 2024, then advanced by 25.85% to $21.9 million in 2025, then sank by 43.26% to $12.4 million in 2026.
- The last three Capital Expenditures figures came in at $12.4 million (Q2 2026), $10.2 million (Q1 2026), and $21.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 12.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.41 Mn |
| Jun 30, 2026 | 12.41 Mn |
| Mar 31, 2026 | 10.20 Mn |
| Mar 31, 2026 | 10.20 Mn |
| Dec 31, 2025 | 21.88 Mn |
| Dec 31, 2025 | 21.88 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Jun 30, 2025 | 19.07 Mn |
| Jun 30, 2025 | 19.07 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 17.38 Mn |
| Dec 31, 2024 | 17.38 Mn |
| Sep 30, 2024 | 5.19 Mn |
| Sep 30, 2024 | 5.19 Mn |
| Jun 30, 2024 | 54.14 Mn |
| Jun 30, 2024 | 54.14 Mn |
| Mar 31, 2024 | 9.55 Mn |
| Mar 31, 2024 | 9.55 Mn |